CD38 and Miyoshi myopathy: Over the past ten years, there are multiple regimens, such as proteasome inhibitors (PIs), immunomodulatory drugs, CAR-T therapy and CD38 monoclonal antibody, which have improved the survival of MM patients significantly (7).